Halle, Germany

Petra Fuchs

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Imtm Gmbh. Active years: 2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Petra Fuchs. Retrieved from https://idiyas.com/inventor/petra-fuchs

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile



Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Petra Fuchs: Innovator in Peptidase Inhibitors

Introduction

Petra Fuchs is a notable inventor based in Halle, Germany. She has made significant contributions to the field of biochemistry, particularly in the development of therapeutic agents. Her work focuses on innovative solutions for inflammatory and other diseases.

Latest Patents

Petra Fuchs holds a patent for "Dual-use peptidase inhibitors as prodrugs for a therapy of inflammatory and other diseases." This patent includes compounds of the general formulae (1) A-B-D-B'-A' and (2) A-B-D-E, which represent her groundbreaking approach to treating various medical conditions.

Career Highlights

Fuchs is associated with Imtm GmbH, where she continues to advance her research and development efforts. Her dedication to innovation has positioned her as a key figure in her field.

Collaborations

Throughout her career, Petra has collaborated with esteemed colleagues such as Siegfried Ansorge and Klaus Neubert. These partnerships have further enriched her research and contributed to her success.

Conclusion

Petra Fuchs exemplifies the spirit of innovation in the realm of biochemistry. Her work on peptidase inhibitors showcases her commitment to improving therapeutic options for patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…